Nebulised procaterol versus nebulised salbutamol for the treatment of moderate acute asthma

The efficacy of nebulised procaterol versus nebulised salbutamol for the treatment of moderate acute asthma: a randomised, double-blind, parallel group study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25669625

Enrollment

140

Registered

2009-08-05

Start date

2007-06-12

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate acute asthma Respiratory Asthma

Interventions

Treatment allocation was according to block randomisation using random permuted blocks of size 4. Patients received either one ampule of procaterol, diluted with 2 ml of normal saline, or one ampule o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with moderate acute asthma according to Global Initiative for Asthma (GINA) 1998 (patients with asthma score 5 to 11; PEFR less than or same 80% predicted) 2. Patients of both genders, aged 15 to 60 years 3. Patients still have the ability to undergo examinations and give written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Smokers 3. Patients with heart disease, hyperthyroidism, diabetes mellitus, chronic obstructive pulmonary disease (COPD) or other chronic diseases 4. Patients with signs of severe infections

Design outcomes

Primary

Measure	Time frame
Difference from baseline in peak expiratory flow rate (PEFR). Measurements performed at 0, 20, 40, 60 and 120 minutes.	—

Secondary

Measure	Time frame
Difference from baseline in asthma score. Measurements performed at 0, 20, 40, 60 and 120 minutes.	—

Countries

Indonesia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026